Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic me… Read more
Iovance Biotherapeutics Inc (IOVA) - Net Assets
Latest net assets as of September 2025: $702.29 Million USD
Based on the latest financial reports, Iovance Biotherapeutics Inc (IOVA) has net assets worth $702.29 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($904.95 Million) and total liabilities ($202.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $702.29 Million |
| % of Total Assets | 77.61% |
| Annual Growth Rate | 120.45% |
| 5-Year Change | 8.21% |
| 10-Year Change | 582.93% |
| Growth Volatility | 598.54 |
Iovance Biotherapeutics Inc - Net Assets Trend (2008–2024)
This chart illustrates how Iovance Biotherapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Iovance Biotherapeutics Inc (2008–2024)
The table below shows the annual net assets of Iovance Biotherapeutics Inc from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $710.40 Million | +21.52% |
| 2023-12-31 | $584.61 Million | +17.01% |
| 2022-12-31 | $499.64 Million | -19.63% |
| 2021-12-31 | $621.66 Million | -5.31% |
| 2020-12-31 | $656.50 Million | +119.59% |
| 2019-12-31 | $298.97 Million | -35.87% |
| 2018-12-31 | $466.19 Million | +220.45% |
| 2017-12-31 | $145.48 Million | -12.84% |
| 2016-12-31 | $166.92 Million | +60.46% |
| 2015-12-31 | $104.02 Million | +131.96% |
| 2014-12-31 | $44.85 Million | +154.75% |
| 2013-12-31 | $17.60 Million | +255.52% |
| 2012-12-31 | $-11.32 Million | +11.43% |
| 2011-12-31 | $-12.78 Million | -2103.01% |
| 2010-12-31 | $638.09K | +4830.76% |
| 2009-12-31 | $-13.49K | -690.54% |
| 2008-12-31 | $2.28K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Iovance Biotherapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 238449328400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.00K | 0.00% |
| Other Comprehensive Income | $-1.05 Million | -0.15% |
| Other Components | $3.10 Billion | 435.81% |
| Total Equity | $710.40 Million | 100.00% |
Iovance Biotherapeutics Inc Competitors by Market Cap
The table below lists competitors of Iovance Biotherapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
$1.03 Billion |
|
Sansera Engineering Limited
NSE:SANSERA
|
$1.03 Billion |
|
Harmonic Inc
NASDAQ:HLIT
|
$1.03 Billion |
|
Cultural Investment Holdings Co Ltd
SHG:600715
|
$1.03 Billion |
|
Anhui Xinlong Electrical Co Ltd
SHE:002298
|
$1.03 Billion |
|
Baoding Lucky Innovative Materials Co Ltd
SHE:300446
|
$1.03 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
$1.03 Billion |
|
NOF Corporation
MU:NOF
|
$1.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Iovance Biotherapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 584,613,000 to 710,405,000, a change of 125,792,000 (21.5%).
- Net loss of 372,177,000 reduced equity.
- New share issuances of 397,304,000 increased equity.
- Other comprehensive income decreased equity by 3,572,000.
- Other factors increased equity by 104,237,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-372.18 Million | -52.39% |
| Share Issuances | $397.30 Million | +55.93% |
| Other Comprehensive Income | $-3.57 Million | -0.5% |
| Other Changes | $104.24 Million | +14.67% |
| Total Change | $- | 21.52% |
Book Value vs Market Value Analysis
This analysis compares Iovance Biotherapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2068.31x to 1.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $0.00 | $3.89 | x |
| 2009-12-31 | $-0.01 | $3.89 | x |
| 2010-12-31 | $0.98 | $3.89 | x |
| 2011-12-31 | $-16.83 | $3.89 | x |
| 2012-12-31 | $-14.18 | $3.89 | x |
| 2013-12-31 | $1.80 | $3.89 | x |
| 2014-12-31 | $1.79 | $3.89 | x |
| 2015-12-31 | $2.34 | $3.89 | x |
| 2016-12-31 | $3.02 | $3.89 | x |
| 2017-12-31 | $2.23 | $3.89 | x |
| 2018-12-31 | $4.79 | $3.89 | x |
| 2019-12-31 | $2.40 | $3.89 | x |
| 2020-12-31 | $4.75 | $3.89 | x |
| 2021-12-31 | $4.05 | $3.89 | x |
| 2022-12-31 | $3.14 | $3.89 | x |
| 2023-12-31 | $2.49 | $3.89 | x |
| 2024-12-31 | $2.45 | $3.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Iovance Biotherapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -226.84%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.28x
- Recent ROE (-52.39%) is above the historical average (-202.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -2501.75% | 0.00% | 0.00x | 2.46x | $-57.37K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.42K |
| 2010 | -252.00% | 0.00% | 0.00x | 2.29x | $-1.67 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.42 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.18 Million |
| 2013 | -144.18% | 0.00% | 0.00x | 1.13x | $-27.14 Million |
| 2014 | -26.84% | 0.00% | 0.00x | 1.04x | $-16.52 Million |
| 2015 | -26.59% | 0.00% | 0.00x | 1.02x | $-38.06 Million |
| 2016 | -31.69% | 0.00% | 0.00x | 1.03x | $-69.59 Million |
| 2017 | -63.28% | 0.00% | 0.00x | 1.07x | $-106.61 Million |
| 2018 | -26.51% | 0.00% | 0.00x | 1.03x | $-170.20 Million |
| 2019 | -62.57% | 0.00% | 0.00x | 1.15x | $-216.97 Million |
| 2020 | -39.54% | 0.00% | 0.00x | 1.17x | $-325.23 Million |
| 2021 | -52.73% | 0.00% | 0.00x | 1.25x | $-389.99 Million |
| 2022 | -78.04% | -163833.19% | 0.00x | 1.33x | $-439.89 Million |
| 2023 | -75.95% | -37345.42% | 0.00x | 1.33x | $-502.50 Million |
| 2024 | -52.39% | -226.84% | 0.18x | 1.28x | $-443.22 Million |
Industry Comparison
This section compares Iovance Biotherapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Iovance Biotherapeutics Inc (IOVA) | $702.29 Million | -2501.75% | 0.29x | $1.03 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |